Fidelity Investments’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Fidelity Investments’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-712,651	Closed	-$1.6M	–	2804
2017 Q4	$1.6M	Hold	712,651	–	–	﹤0.01%	2383
2017 Q3	$2.42M	Hold	712,651	–	–	﹤0.01%	2296
2017 Q2	$2.53M	Hold	712,651	–	–	﹤0.01%	2309
2017 Q1	$2.42M	Hold	712,651	–	–	﹤0.01%	2328
2016 Q4	$3.28M	Sell	712,651 -71,440	-9%	-$295K	﹤0.01%	2278
2016 Q3	$3.33M	Hold	784,091	–	–	﹤0.01%	2270
2016 Q2	$1.88M	Sell	784,091 -134,234	-15%	-$485K	﹤0.01%	2394
2016 Q1	$4.32M	Sell	918,325 -53,840	-6%	-$208K	﹤0.01%	2196
2015 Q4	$3.82M	Hold	972,165	–	–	﹤0.01%	2275
2015 Q3	$3.76M	Sell	972,165 -11,500	-1%	-$52.8K	﹤0.01%	2263
2015 Q2	$4.53M	Buy	983,665 +2,800	+0.3%	+$26.8K	﹤0.01%	2270
2015 Q1	$6.61M	Hold	980,865	–	–	﹤0.01%	2143
2014 Q4	$3.17M	Buy	+980,865	New	+$3.95M	﹤0.01%	2346

Other funds holding AST

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Fidelity Investments's AST Position: Q1 2018 in Review

Fidelity Investments sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2018, closing a stake of 712,651 shares — an estimated $1.6M sold.

Fidelity Investments first reported a position in AST in Q4 2014 and held it in 13 quarters. The position peaked at $6.61M in Q1 2015. 72 funds tracked by Wall St. Rank hold AST as of Q1 2018.

Fidelity Investments reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2018 after selling out during the quarter.
Fidelity Investments sold 712,651 Asterias Biotherapeutics Inc. Series A shares in Q1 2018, an estimated $1.6M.
Fidelity Investments first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2014 and held it in 13 quarters.
Fidelity Investments's Asterias Biotherapeutics Inc. Series A position peaked at $6.61M in Q1 2015.
72 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2018.

Based on Fidelity Investments's 13F filing for Q1 2018, filed 14 May 2018.